Aventis Ad Campaign Challenges Sanofi Merger Bid
This article was originally published in The Pink Sheet Daily
Executive Summary
Aventis has launched an advertising campaign in European newspapers and magazines arguing against Sanofi-Synthelabo's $60 bil. hostile takeover bid
You may also be interested in...
Sanofi-Aventis/Altana's Asthma Therapy Alvesco Is "Approvable"
FDA says the review decision came directly from ODE II rather than the Division of Pulmonary & Allergy Drug Products. Aventis had touted Alvesco as one of six product launches that would drive organic growth during its attempts to fend off Sanofi's merger bid.
Sanofi-Aventis/Altana's Asthma Therapy Alvesco Is "Approvable"
FDA says the review decision came directly from ODE II rather than the Division of Pulmonary & Allergy Drug Products. Aventis had touted Alvesco as one of six product launches that would drive organic growth during its attempts to fend off Sanofi's merger bid.
GlaxoSmithKline Will Buy Arixtra, Fraxiparine In Event Of Sanofi/Aventis Merger
GSK would pay $541 mil. for the two anti-thrombotic agents and a manufacturing facility in France. The sale represents a preemptive divestiture on Sanofi's part; both products compete with Aventis' Lovenox.